Trial reportMuscle & nerve2017
Assessing mNIS+7
Abstract readClinical Trial, Phase IIIMulticenter Study
In one paragraph
Trial report in Muscle & nerve, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Pharmacological treatment for familial amyloid polyneuropathy.The Cochrane database of systematic reviews · 2020Pooled it
- Neurological efficacy and safety of RNA therapeutics in hereditary transthyretin amyloidosis: a systematic review and meta-analysis of randomized controlled trials.Therapeutic advances in cardiovascular diseasePooled it
- mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin-mediated amyloidosis.Muscle & nerve · 2020Trial
- Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis.Journal of neurology · 2020Trial
- Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.The New England journal of medicine · 2018Trial
- Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy.BMC neurology · 2017Trial
- Clinical Diabetic Peripheral Neuropathy: Can It Be Reversed? Arguments for and Against From a NEUROdiab Debate.Journal of the peripheral nervous system : JPNS · 2026Review
- Peripheral Neuropathy: A Phenotype-Driven Review for Diagnosis and Management.Revista de neurologia · 2026Review
- Peripheral Nervous, Hepatic, and Gastrointestinal Endpoints for AL Amyloidosis Clinical Trials: Report from the Amyloidosis Forum Multi-organ System Working Group.Advances in therapy · 2023Review
- Composite nerve conduction scores and signs for diagnosis and somatic staging of diabetic polyneuropathy: Mid North American ethnic cohort survey.Muscle & nerve · 2023Article
- Quantitative thermal testing as a screening and follow-up tool for diabetic sensorimotor polyneuropathy in patients with type 2 diabetes and prediabetes.Frontiers in neuroscience · 2023Article
- Responder analysis for neuropathic impairment and quality-of-life assessment in patients with hereditary transthyretin amyloidosis with polyneuropathy in the NEURO-TTR study.Journal of neurology · 2022Article
- Hereditary Transthyretin Amyloidosis with Polyneuropathy: Monitoring and Management.International journal of general medicine · 2022Review
- Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression.Orphanet journal of rare diseases · 2021Article
- Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.Journal of neurology · 2021Review
- Patient-reported outcomes on familial amyloid polyneuropathy (FAP).Orphanet journal of rare diseases · 2020Article
- The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.PLoS medicine · 2019Article
- Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2019Review
- Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease.Nature reviews. Neurology · 2019Review
- Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin Amyloidosis.Pharmaceuticals (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors at 18 institutions in 6 countries.
Peter J DyckDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota, 55905, USA.
John C KincaidIndiana University, IU Health, Indianapolis, Indiana, USA.
P James B DyckDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota, 55905, USA.
Vinay ChaudhryJohns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Namita A GoyalUniversity of California Irvine, Irvine, California, USA.
Christina AlvesHospital Santo António, Centro Hospitalar Porto, Porto, Portugal.
Hayet SalhiHôpitaux Universitaires Henri Mondor, Créteil, France.
Janice F WiesmanBoston Medical Center, Boston, Massachusetts, USA.
Celine LabeyrieCHU Bicêtre, French Reference Center for FAP (NNERF), Le Kremlin Bicêtre, France.
Jessica Robinson-PappIcahn School of Medicine at Mount Sinai, New York, New York, USA.
Márcio CardosoHospital Santo António, Centro Hospitalar Porto, Porto, Portugal.
Matilde LauraNational Hospital for Neurology and Neurosurgery, London, United Kingdom.
Katherine RuzhanskyMedical University of South Carolina, Charleston, South Carolina, USA.
Andrea CorteseC. Mondino National Neurological Institute, Pavia, Italy.
Thomas H BrannaganColumbia University, New York, New York, USA.
Julie KhouryOregon Health & Science University, Portland, Oregon, USA.
Sami KhellaPenn Presbyterian Medical Center, Philadelphia, Pennsylvania, USA.
Márcia Waddington-CruzClementino Fraga Filho University Hospital, Federal University of Rio de Janerio, Rio de Janerio, Brazil.
João FerreiraNew University of Lisbon, Lisbon, Portugal.
Annabel K WangUniversity of California-Irvine, Orange, California, USA.
Marcus V PintoClementino Fraga Filho University Hospital, Federal University of Rio de Janerio, Rio de Janerio, Brazil.
Samar S AyacheHôpitaux Universitaires Henri Mondor, Créteil, France.
Merrill D BensonIndiana University School of Medicine, Indianapolis, Indiana, USA.
John L BerkBoston University School of Medicine, Boston, Massachusetts, USA.
Teresa CoelhoHospital Santo António, Centro Hospitalar Porto, Porto, Portugal.
Michael PolydefkisJohns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Peter GorevicIcahn School of Medicine at Mount Sinai, New York, New York, USA.
David H AdamsCHU Bicêtre, French Reference Center for FAP (NNERF), Le Kremlin Bicêtre, France.
Violaine Plante-BordeneuveHôpitaux Universitaires Henri Mondor, Créteil, France.
Carol WhelanNational Hospital for Neurology and Neurosurgery, London, United Kingdom.
Giampaolo MerliniFoundation IRCCS Policlinico San Matteo, University of Pavia, Italy.
Stephen HeitnerOregon Health & Science University, Portland, Oregon, USA.
Brian M DrachmanPenn Presbyterian Medical Center, Philadelphia, Pennsylvania, USA.
Isabel ConceiçãoNew University of Lisbon, Lisbon, Portugal.
Christopher J KleinDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota, 55905, USA.
Morie A GertzDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota, 55905, USA.
Elizabeth J AckermannIonis Pharmaceuticals, Inc, Carlsbad, California, USA.
Steven G HughesIonis Pharmaceuticals, Inc, Carlsbad, California, USA.
Michelle L MauermannDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota, 55905, USA.
Rito BergemannGlaxoSmithKline, Middlesex, United Kingdom.
Karen A LodermeierDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota, 55905, USA.
Jenny L DaviesDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota, 55905, USA.
Rickey E CarterDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota, 55905, USA.
William J LitchyDepartment of Neurology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota, 55905, USA.
Mayo Clinic · USCentro Hospitalar do Porto · PTOregon Health & Science University · USUniversity of California, Irvine · USBoston Medical Center · USBoston University · USHôpitaux Universitaires Henri-Mondor · FRIndiana University Health · USIscte – Instituto Universitário de Lisboa · PTJohns Hopkins University · USMedical University of South Carolina · USNational Hospital for Neurology and Neurosurgery · GBPenn Presbyterian Medical Center · USUniversity of Lisbon · PTFondazione Istituto Neurologico Nazionale Casimiro Mondino · ITGlaxoSmithKline (United Kingdom) · GBHospital Universitário Clementino Fraga Filho · BRUniversity of Pavia · IT
Funding
Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2MUniversity of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1MThe Manhattan HIV Brain BankU24MH100931 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MORGELLO, SUSAN · 2013 to 2023
$14.0MDIABETIC NEUROPATHY STUDYR01NS036797 · NINDS · MAYO CLINIC ROCHESTER · PI DYCK, PETER JAMES · 1997 to 2008
$6.8MAutonomic neuropathy, gastrointestinal motility, and inflammation in HIVR21DK105917 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ROBINSON-PAPP, JESSICA · 2015 to 2016
$458kSTRUCTURE, TURNOVER, &FUNCTION OF MEMBRANE PHOSPHOLIPIDS IN NEUROPATHIESP01NS014304 · NINDS · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI WINDEBANK, ANTHONY J · 1985 to 1996
–NCATS NIH HHS UL1 TR000135NCATS NIH HHS UL1 TR001414NIDDK NIH HHS R21 DK105917NIMH NIH HHS U24 MH100931NINDS NIH HHS P01 NS014304NINDS NIH HHS R01 NS036797
Abstract
introductionPolyneuropathy signs (Neuropathy Impairment Score, NIS), neurophysiologic tests (m+7
methodsWe assessed: (1) Proficiency of grading neurologic signs and correlation with neurophysiologic tests, and (2) clinometric performance of modified NIS+7 neurophysiologic tests (mNIS+7
resultsThe mNIS+7
conclusionsSpecially trained neurologists accurately assessed neuropathy signs as compared to referenced neurophysiologic tests. The score, mNIS+7
Indexed as
Diagnostic Techniques, NeurologicalNeurologistsSeverity of Illness IndexAdultAgedAged, 80 and overAmyloid Neuropathies, FamilialCohort StudiesDisability EvaluationFemaleHumansInternational CooperationMaleMiddle AgedNeural ConductionOligonucleotidesOligonucleotidesdisabilityfamilial amyloidotic polyneuropathy (FAP)neurophysiologic testsoligonucleotide trialsperipheral neuropathypolyneuropathy signsproficiency
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.